Past Solicitations
BAA 14-003 Call 0012
African Swine Fever Antigen

Chemical and Biological Research and Development CBD.07 Vaccines and Therapeutics: New, cost-effective, biological-based countermeasures for foreign animal disease (FAD) and zoonotic pathogens affecting major domestic livestock species. Specific areas of interest are cattle and swine product candidates based on molecular or recombinant vaccine platforms previously shown to be safe and effective against other infectious animal or human biodefense disease targets, panvalent vaccines and novel biological-derived broad spectrum antiviral agents with an established immune-based mechanism of action. (1) New, molecular-based or recombinant vaccine candidates that improve the onset of protective immunity and can differentiate infected from vaccinated animals. (2) Novel immunostimulants, adjuvants, or biological-based agents with an immune-based mechanism of action that can improve pathogen-specific vaccine efficacy and/or vaccine potency. (3) New molecular or recombinant-based vaccines that can increase spectrum of cross-protection against related strains. (4) New molecular or recombinant-based vaccines based on innovative state-of-the-art technologies (e.g., nanovaccines, VLPs). (5) New biological-based broad spectrum anti-viral therapeutics ( small molecule drugs excluded) that can be used in combination with pathogen-specific vaccines Department of Homeland Security (DHS) Science and Technology Directorate (S&T) Chemical and Biological Defense Division (CBD) BAA 14-003/Call 0012 Call 0012 Page 2 (6) Novel high throughput vaccine or biological delivery systems for livestock. NOTE: Influenza countermeasure proposals will not be considered.

Topics

TTA-1 - Production of Recombinant Subunit ASF Virus (ASFV) Antigens

The goal of Technical Topic Area 1 is to express and purify individual ASFV open reading frames (ORFs) of known and more preferably, of unknown function, using a baculovirus expression system that has the co-capability for recombinant ASFV subunit expression in insect and mammalian cells. For details, please refer to the solicitation details located at FedBizOpps website.

TTA-2 - Vaccine Vector Platforms for Presentation of ASF Virus (ASFV) Subunit Antigens

The goal of Technical Topic Area 2 is to develop new or next generation (adapted) of previously used vaccine vector platforms (e.g., replication deficient human adenovirus; modified vaccinia)with the potential to simultaneously express and present multiple ASFV open reading frames (ORFs) in a context similar to a natural ASFV infection. For details, please refer to the solicitation details located at FedBizOpps website.

Key Dates
Solicitation Open Date:
07/23/2015
Registration Deadline:
08/22/2015 01:00 PM ET
Submission Deadline:
08/22/2015 01:00 PM ET


Amendments and Q&As
amendment icon Amendment # 2
Posted Date 8/10/15

( Part of Amendment 1 (listed above): The purpose of this amendment is to post answers to industry qu ...)
(Read Full)

Part of Amendment 1 (listed above): The purpose of this amendment is to post answers to industry questions and to provide clarification in the solicitation (changes in the solicitation document is highlighted in yellow).


amendment icon Amendment # 1
Posted Date 8/10/15

( Amendment 1: The purpose of this amendment is to post answers to industry questions and to provide ...)
(Read Full)

Amendment 1: The purpose of this amendment is to post answers to industry questions and to provide clarification in the solicitation (changes in the solicitation document is highlighted in yellow).




Back to Past Solicitations List